Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer
出版年份 2015 全文链接
标题
Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer
作者
关键词
-
出版物
Future Oncology
Volume 11, Issue 4, Pages 629-640
出版商
Future Medicine Ltd
发表日期
2015-02-17
DOI
10.2217/fon.14.279
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H)
- (2014) J. Goldstein et al. ANNALS OF ONCOLOGY
- Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features
- (2014) E. Missiaglia et al. ANNALS OF ONCOLOGY
- Patient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147
- (2014) Wilson I. Gonsalves et al. JNCI-Journal of the National Cancer Institute
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
- (2014) Volker Heinemann et al. LANCET ONCOLOGY
- RAS Mutation Status Predicts Survival and Patterns of Recurrence in Patients Undergoing Hepatectomy for Colorectal Liver Metastases
- (2013) Jean-Nicolas Vauthey et al. ANNALS OF SURGERY
- KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers
- (2013) A I Phipps et al. BRITISH JOURNAL OF CANCER
- The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer
- (2013) V Eklöf et al. BRITISH JOURNAL OF CANCER
- Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases
- (2013) Georgios Karagkounis et al. CANCER
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Pooled Analysis From Seven Randomized Controlled Trials
- (2013) H. I. Hurwitz et al. ONCOLOGIST
- The impact of comorbidity on cancer survival: a review
- (2013) Mette Sogaard et al. Clinical Epidemiology
- Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive Norwegian series
- (2012) M. A. Merok et al. ANNALS OF ONCOLOGY
- The relationship between tumour site, clinicopathological characteristics and cancer-specific survival in patients undergoing surgery for colorectal cancer
- (2012) A. G. M. T. Powell et al. Colorectal Disease
- Mutant KRAS Codon 12 and 13 Alleles in Patients With Metastatic Colorectal Cancer: Assessment As Prognostic and Predictive Biomarkers of Response to Panitumumab
- (2012) Marc Peeters et al. JOURNAL OF CLINICAL ONCOLOGY
- BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
- (2011) T Yokota et al. BRITISH JOURNAL OF CANCER
- Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer
- (2011) Ben Tran et al. CANCER
- Comparison of 17,641 Patients With Right- and Left-Sided Colon Cancer: Differences in Epidemiology, Perioperative Course, Histology, and Survival
- (2011) Frank Benedix et al. DISEASES OF THE COLON & RECTUM
- Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
- (2011) Timothy S Maughan et al. LANCET
- PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers
- (2011) Filip Janku et al. PLoS One
- Activating K-Ras mutations outwith ‘hotspot’ codons in sporadic colorectal tumours – implications for personalised cancer medicine
- (2010) G Smith et al. BRITISH JOURNAL OF CANCER
- Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab
- (2010) Jolien Tol et al. EUROPEAN JOURNAL OF CANCER
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer
- (2009) J Souglakos et al. BRITISH JOURNAL OF CANCER
- KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
- (2009) F Loupakis et al. BRITISH JOURNAL OF CANCER
- KRASandBRAFMutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial
- (2009) Susan D. Richman et al. JOURNAL OF CLINICAL ONCOLOGY
- PIK3CAMutation Is Associated With Poor Prognosis Among Patients With Curatively Resected Colon Cancer
- (2009) Shuji Ogino et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
- (2008) F. Perrone et al. ANNALS OF ONCOLOGY
- Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group
- (2008) C. I. Müller et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
- Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
- (2008) Carsten Bokemeyer et al. JOURNAL OF CLINICAL ONCOLOGY
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation